Beam Therapeutics
BEAM
221 hedge funds and large institutions have $1.94B invested in Beam Therapeutics in 2024 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 75 increasing their positions, 67 reducing their positions, and 19 closing their positions.
94% more call options, than puts
Call options by funds: $12.1M | Put options by funds: $6.22M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
42% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 19
12% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 67
6% more capital invested
Capital invested by funds: $1.82B → $1.94B (+$117M)
3% more funds holding
Funds holding: 214 → 221 (+7)
1.63% more ownership
Funds ownership: 94.28% → 95.9% (+1.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
+$34.3M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$34.3M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$33.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$18.8M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$12.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$37.8M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$28.3M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$21.1M |
| 4 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$15.7M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$10.1M |
BEAM Hedge Fund Activity: Q3 2024 in Review
221 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q3 2024, worth a combined $1.94B — up 6.4% from $1.82B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new BEAM positions and 19 closed out — a net gain of 8 holders — while 75 added to existing stakes and 67 trimmed.
The largest buyer was Nikko Asset Management Americas, adding an estimated $34.3M. The largest seller was First Trust Advisors, cutting an estimated $37.8M.
- 221 institutional investors held Beam Therapeutics (BEAM) as of Q3 2024, up from 214 in Q2 2024.
- Funds reported $1.94B of Beam Therapeutics stock for Q3 2024, up 6.4% quarter-over-quarter.
- 27 funds opened new Beam Therapeutics positions in Q3 2024 and 19 closed out, a net change of +8 holders.
- The largest Beam Therapeutics buyer in Q3 2024 was Nikko Asset Management Americas, an estimated $34.3M added.
- The largest Beam Therapeutics seller in Q3 2024 was First Trust Advisors, an estimated $37.8M sold.
Based on aggregated 13F filings for Q3 2024.